# Zoetis Inc. (ZTS)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $36.13B  
**Price:** $81.40 (+0.14%)

> Zoetis Inc. is a global animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health solutions. Its products serve both companion animals, such as dogs, cats, and horses, and livestock, including cattle, swine, poultry, fish, and sheep. Zoetis offers a broad portfolio spanning parasiticides, vaccines, dermatology treatments, anti-infectives, pain and sedation therapies, and nutritional and other non-pharmaceutical products, supported by point-of-care diagnostic tools, laboratory services, and monitoring technologies. The company markets its solutions primarily to veterinarians, livestock producers, and pet owners, playing a key role in supporting animal health, food production efficiency, and pet care standards worldwide. Zoetis Inc. operates across the United States and international markets and is headquartered in Parsippany, New Jersey.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $9.47B | — | — | $2.67B | — |
| 2024 | $9.26B | — | — | $2.49B | — |
| 2023 | $8.54B | — | — | $2.34B | — |
| 2022 | $8.08B | — | — | $2.11B | — |
| 2021 | $7.78B | — | — | $2.04B | — |
| 2020 | $6.67B | — | — | $1.64B | — |
| 2019 | $6.26B | — | — | $1.50B | — |
| 2018 | $5.83B | — | — | $1.43B | — |
| 2017 | $5.31B | — | — | $864M | — |
| 2016 | $4.89B | — | — | $821M | — |
| 2015 | $4.76B | — | — | $339M | — |
| 2014 | $4.79B | — | — | $583M | — |
| 2013 | $4.56B | — | — | $504M | — |
| 2012 | $4.34B | — | — | $436M | — |
| 2011 | $4.23B | — | — | $245M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $15.49B | $12.07B | $3.42B | $2.45B | $9.04B |
| 2024 | $14.24B | $9.47B | $4.77B | $1.99B | $5.22B |
| 2023 | $14.29B | $9.29B | $5.00B | $2.04B | $6.56B |
| 2022 | $14.93B | $10.52B | $4.41B | $3.58B | $6.55B |
| 2021 | $13.90B | $9.36B | $4.54B | $3.48B | $6.59B |
| 2020 | $13.61B | $9.84B | $3.77B | $3.60B | $6.59B |
| 2019 | $11.54B | $8.84B | $2.71B | $1.93B | $5.95B |
| 2018 | $10.78B | $8.59B | $2.19B | $1.60B | $6.44B |
| 2017 | $8.59B | $6.80B | $1.77B | $1.56B | $4.95B |
| 2016 | $7.65B | $6.15B | $1.49B | $727M | $4.47B |
| 2015 | $7.91B | $6.82B | $1.07B | $1.15B | $4.46B |
| 2014 | $6.59B | $5.25B | $1.31B | $882M | $3.62B |
| 2013 | $6.56B | $5.60B | $940M | $610M | $3.64B |
| 2012 | $6.26B | $2.22B | $4.03B | $317M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $2.90B | $621M | $2.28B |
| 2024 | $2.95B | $655M | $2.30B |
| 2023 | $2.35B | $732M | $1.62B |
| 2022 | $1.91B | $586M | $1.33B |
| 2021 | $2.21B | $477M | $1.74B |
| 2020 | $2.13B | $453M | $1.67B |
| 2019 | $1.79B | $460M | $1.33B |
| 2018 | $1.79B | $338M | $1.45B |
| 2017 | $1.35B | $224M | $1.12B |
| 2016 | $713M | $216M | $497M |
| 2015 | $664M | $224M | $440M |
| 2014 | $626M | $180M | $446M |
| 2013 | $681M | $184M | $497M |
| 2012 | $454M | $126M | $328M |
| 2011 | $497M | $135M | $362M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ZTS)